NOTE 1 - BASIS OF PRESENTATION (Details) - Sangui BioTech GmbH |
12 Months Ended |
---|---|
Jun. 30, 2022 | |
Equity Method Investment, Ownership Percentage | 90.00% |
Equity Method Investment, Additional Information | Effective from June 18, 2018 Sangui BioTech GmbH together with Mölnlycke Health Care GmbH (former: Sastomed GmbH) founded Sangui Know-How- und Patentverwertungsgesellschaft mbH & Co. KG (“Sangui KG”). Sangui KG is a limited partnership, with Sangui BioTech GmbH as the general partner (owing 99.8%) and Mölnlycke Health Care GmbH as a limited partner (owning 0.2%) |